EKF Diagnostics Holdings Plc (AIM: EKF), the AIM-traded medical diagnostics business, has recently announced that Renalytix AI Plc, a spin-out from EKF, has conditionally raised gross funds of a minimum of £21 million in connection with its previously announced equity Fundraising, and the admission of its shares to trading on the London Stock Exchange’s Alternative Investment Market (“AIM”). 

The Company is now pleased to confirm that a restricted offer is being launched in connection with the equity fundraising, which will enable certain EKF shareholders in the UK to subscribe for RenalytixAI ordinary shares of nominal value £0.0025 each (following a proposed subdivision of its current £0.01 ordinary shares) (“RENX Shares”) in connection with the Fundraising at a price of £1.21 per share.

RenalytixAI is a developer of artificial intelligence (“AI”) enabled clinical decision support solutions for kidney disease, one of the most common and costly chronic medical conditions globally. RenalytixAI’s solutions are being designed to make significant improvements in kidney disease risk assessment, clinical care, patient stratification for drug clinical trials, and drug target discovery.

Singer Capital Markets are acting as Nominated Adviser and Broker.

[follow align=”center” twitter=”https://twitter.com/nplus1singer” linkedin=”https://www.linkedin.com/company/274452/”]